U.S. FDA issues five observations to Aurobindo Pharma arm’s API plant
We will respond to the U.S. FDA within the stipulated timelines, Aurobindo Pharma said
We will respond to the U.S. FDA within the stipulated timelines, Aurobindo Pharma said
What's Your Reaction?
